Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Von Eschenbach’s Commissioner Debut May Be Release Of Safety Report

Executive Summary

One of Andrew von Eschenbach's first major steps as FDA commissioner is likely to be release of the agency task force response to the Institute of Medicine's recommendations to improve drug safety oversight
Advertisement

Related Content

Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Sen. Baucus “Expects Answers” On Sen. Grassley’s FDA Inquiries
Sen. Baucus “Expects Answers” On Sen. Grassley’s FDA Inquiries
Separate Safety Center Could Impair Oversight “Continuity” - Von Eschenbach
Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In
Gottlieb’s New Year’s Wish List: Risk Management Plans Out, Science In
Crawford’s First Business After Confirmation: Brief Senators On Mifeprex
Advertisement
UsernamePublicRestriction

Register

PS047837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel